US4507237A - 2-[(2-Methoxy-5-halo)azo]-1-H-imidazoles and method of production of 2-[(2-methoxy)azo]-1-H-imidazoles - Google Patents

2-[(2-Methoxy-5-halo)azo]-1-H-imidazoles and method of production of 2-[(2-methoxy)azo]-1-H-imidazoles Download PDF

Info

Publication number
US4507237A
US4507237A US06/173,359 US17335980A US4507237A US 4507237 A US4507237 A US 4507237A US 17335980 A US17335980 A US 17335980A US 4507237 A US4507237 A US 4507237A
Authority
US
United States
Prior art keywords
compound
parts
azo
methoxy
imidazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US06/173,359
Inventor
Isao Niimura
Shigeo Maeda
Hideo Okazaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hodogaya Chemical Co Ltd
Mochida Pharmaceutical Co Ltd
Original Assignee
Hodogaya Chemical Co Ltd
Mochida Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hodogaya Chemical Co Ltd, Mochida Pharmaceutical Co Ltd filed Critical Hodogaya Chemical Co Ltd
Assigned to HODOGAYA CHEMICAL CO., LTD., MOCHIDA SEIYAKU KABUSHIKI KAISHA reassignment HODOGAYA CHEMICAL CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: KOSUZUME, HIROSHI, MOCHIDA EI, OHNISHI, HARUO, SUZUKI, YASUO
Application granted granted Critical
Publication of US4507237A publication Critical patent/US4507237A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09BORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B29/00Monoazo dyes prepared by diazotising and coupling
    • C09B29/34Monoazo dyes prepared by diazotising and coupling from other coupling components
    • C09B29/36Monoazo dyes prepared by diazotising and coupling from other coupling components from heterocyclic compounds
    • C09B29/3604Monoazo dyes prepared by diazotising and coupling from other coupling components from heterocyclic compounds containing only a nitrogen as heteroatom
    • C09B29/3647Monoazo dyes prepared by diazotising and coupling from other coupling components from heterocyclic compounds containing only a nitrogen as heteroatom containing a five-membered ring with two nitrogen atoms as heteroatoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88Nitrogen atoms, e.g. allantoin

Definitions

  • the present invention relates to novel azo compounds and a process for preparing the same and, more particularly, to the azo compounds and a process for preparing the azo compounds represented by the formula: ##STR2## wherein X is hydrogen or halogen.
  • the azo compounds are useful as precursors of disperse dyes and basic dyes and are effective for therapeutic treatment.
  • azo compounds are known to be useful as dyes including disperse and basic dyes. It is also known that imidazole can be a component to form various azo compounds. It is not known, however, that the azo compounds of the above formula can be basic and disperse dyes and that in particular they are effective for therapeutic treatment.
  • the object of the present invention is to provide novel azo compounds having the formula as represented hereinabove.
  • Another object of the present invention is to provide novel azo compounds which are useful as precursors for the production of disperse and/or basic dyes as well as effective as therapeutic agents.
  • a further object of the present invention is to provide a process for preparing the azo compounds having the formula as represented hereinabove without any substantial production of by-products.
  • the azo compounds according to the present invention include the azo compounds represented by the formula: ##STR3## wherein X is hydrogen or halogen, and acid addition salts thereof.
  • X is hydrogen or halogen
  • halogen is intended to mean chlorine, bromine, fluorine and iodine.
  • the azo compounds may be converted in a conventional manner into their acid addition salts including an inorganic acid addition salt such as hydrochloride, hydrobromide, sulfate, nitrate and phosphate, and an organic acid addition salt such as acetate, succinate, maleate, oxalate and tartrate.
  • the azo compounds according to the present invention may be prepared by first reacting a 2-methoxyaniline or a reactive derivative thereof with sodium nitrite in the presence of hydrochloric acid and then coupling the resulting diazonium compound to imidazole in an amount of from approximately 5 to 10 moles based on the diazonium compound and, if desired, converting the azo compound into the corresponding acid addition salt.
  • the diazotization of a 2-methoxy aniline with a nitrite and hydrochloric acid may be carried out in conventional manner.
  • the reaction conditions may be conventional and selected depending upon the type of reactants and other conditions.
  • the resulting diazonium compounds are then coupled to imidazole by reacting the former with the latter in an amount of from approximately 5 to 10 moles based on the diazonium compound.
  • the resulting diazonium compounds may be used for the coupling reaction with or without being separated from the mixture where the diazonium compounds are formed.
  • This reaction may be carried out in the presence of an alkali such as sodium hydroxide, potassium hydroxide or sodium carbonate or a buffer such as sodium acetate at a temperature of from 0° to 5° C. for about 1 hour. It is obvious that the reaction conditions with respect to the reaction time and temperature or the like may be varied depending upon the types of the reactants and solvents and the like.
  • the azo compounds according to the present invention exhibit pharmaceutical and therapeutic effects on hypotension, cardiac insufficiency or mucosa hyperemia.
  • 2-[(2-methoxy-5-chlorophenyl)azo]-1H-imidazole and 2-[(2-methoxy-5-bromophenyl)azo]-1H-imidazole possess a diuretic activity about 10 times that of furosemide as a control, when applied to rats, and the other compounds are also higher in diuretic activity than furosemide. It is also seen that the azo compounds have an acute toxicity low enough to cause no problem in a usual application.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

There are disclosed azo compounds represented by the formula: ##STR1## wherein X is hydrogen or halogen. The azo compounds are useful as precursors of disperse dyes and basic dyes and are effective for therapeutic treatment.

Description

BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to novel azo compounds and a process for preparing the same and, more particularly, to the azo compounds and a process for preparing the azo compounds represented by the formula: ##STR2## wherein X is hydrogen or halogen. The azo compounds are useful as precursors of disperse dyes and basic dyes and are effective for therapeutic treatment.
2. Brief Description of Prior Art
Generally, azo compounds are known to be useful as dyes including disperse and basic dyes. It is also known that imidazole can be a component to form various azo compounds. It is not known, however, that the azo compounds of the above formula can be basic and disperse dyes and that in particular they are effective for therapeutic treatment.
It is generally known that, when imidazole is used as a coupling component of azo compounds, it is usually employed in an amount of from about 1 to 1.5 moles based on a diazo component to which imidazole is coupled. In this case, however, the reaction permits the production of by-products in which the diazo component may be coupled to the 4-imidazolyl group or one more diazo components may be coupled to the 4-imidazolyl group. Accordingly, this reaction has a drawback in not providing the azo compounds in a pure form.
SUMMARY OF THE INVENTION
Accordingly, the object of the present invention is to provide novel azo compounds having the formula as represented hereinabove.
Another object of the present invention is to provide novel azo compounds which are useful as precursors for the production of disperse and/or basic dyes as well as effective as therapeutic agents.
A further object of the present invention is to provide a process for preparing the azo compounds having the formula as represented hereinabove without any substantial production of by-products.
Other objects, advantages and features of the present invention will become apparent during the course of the description which follows, but any modifications and improvements to be obviously made should be understood not to deviate from the scope of the present invention.
DETAILED DESCRIPTION OF THE INVENTION
The azo compounds according to the present invention include the azo compounds represented by the formula: ##STR3## wherein X is hydrogen or halogen, and acid addition salts thereof. The term "halogen" is intended to mean chlorine, bromine, fluorine and iodine. The azo compounds may be converted in a conventional manner into their acid addition salts including an inorganic acid addition salt such as hydrochloride, hydrobromide, sulfate, nitrate and phosphate, and an organic acid addition salt such as acetate, succinate, maleate, oxalate and tartrate.
The azo compounds according to the present invention may be prepared by first reacting a 2-methoxyaniline or a reactive derivative thereof with sodium nitrite in the presence of hydrochloric acid and then coupling the resulting diazonium compound to imidazole in an amount of from approximately 5 to 10 moles based on the diazonium compound and, if desired, converting the azo compound into the corresponding acid addition salt.
The diazotization of a 2-methoxy aniline with a nitrite and hydrochloric acid may be carried out in conventional manner. The reaction conditions may be conventional and selected depending upon the type of reactants and other conditions.
The resulting diazonium compounds are then coupled to imidazole by reacting the former with the latter in an amount of from approximately 5 to 10 moles based on the diazonium compound. The resulting diazonium compounds may be used for the coupling reaction with or without being separated from the mixture where the diazonium compounds are formed. This reaction may be carried out in the presence of an alkali such as sodium hydroxide, potassium hydroxide or sodium carbonate or a buffer such as sodium acetate at a temperature of from 0° to 5° C. for about 1 hour. It is obvious that the reaction conditions with respect to the reaction time and temperature or the like may be varied depending upon the types of the reactants and solvents and the like.
The azo compounds according to the present invention exhibit pharmaceutical and therapeutic effects on hypotension, cardiac insufficiency or mucosa hyperemia.
It is shown that in particular, 2-[(2-methoxy-5-chlorophenyl)azo]-1H-imidazole and 2-[(2-methoxy-5-bromophenyl)azo]-1H-imidazole possess a diuretic activity about 10 times that of furosemide as a control, when applied to rats, and the other compounds are also higher in diuretic activity than furosemide. It is also seen that the azo compounds have an acute toxicity low enough to cause no problem in a usual application.
The following examples serve as an illustration of the present invention, but it should be understood that they are not intended at all in any sense to restrict the present invention thereto. In the examples, the unit "parts" is represented in parts by weight.
EXAMPLE 1
To a solution of 5.1 parts of 4-chloro-2-aminoanisole and 7.6 parts of 35% hydrochloric acid in 50 parts of water was added 15 parts of water containing 2.2 parts of sodium nitrite at 0°-5° C., and then the diazotization reaction was carried out by stirring the mixture at 0°-5° C. for 1 hour. The resulting diazonium salt solution was then added at 0°-5° C. to a solution of 20.4 parts of imidazole, 1.7 parts of sodium hydroxide and 2.5 parts of sodium acetate in 150 parts of water, and the mixture was stirred at the same temperature for 1 hour to complete the coupling reaction, thereby forming a crude yellow-orange product. The crude product was filtered, washed with water, and dried at 60° C. to provide 7.6 parts of the product.
This crude product (7 parts) was then recrystallized from n-propylalcohol to provide 4.9 parts of 2-[(2-methoxy-5-chlorophenyl)azo]-1H-imidazole as a yellow-orange columnar crystalline substance. It melted at 205° C. (decomposed), when measured in accordance with the designation of the Japanese Pharmacopeia and had a maximum ultraviolet absorption spectrum (λmax) at 384 mμ.
Elementary Analysis:
______________________________________                                    
            C    H         N      Cl                                      
______________________________________                                    
Calculated (%)                                                            
              50.75  3.83      23.68                                      
                                    14.98                                 
Found (%)     50.55  4.01      24.10                                      
                                    15.05                                 
______________________________________                                    
EXAMPLE 2
2.82 parts of 4-fluoro-2-aminoanisole and 5.2 parts of 35% hydrochloric acid were added to 50 parts of water. To this mixture was added 10 parts of water containing 1.38 parts of sodium nitrite at 0°-5° C., and then the mixture was stirred for 1 hour to effect diazotiaztion. The resulting diazonium salt solution was then added at 0°-5° C. to a solution of 13.6 parts of imidazole, 1.2 parts of sodium hydroxide and 1.64 parts of sodium acetate in 100 parts of water, and the coupling reaction was carried out by stirring the mixture for 1 hour. The yellow-orange azo compound precipitated in the reaction mixture was filtered, washed with water, and then dried at 60° C., thereby giving 4.3 parts of the crude azo compound.
The crude product (4 parts) was then recrystallized from n-butylalcohol to provide 2.9 parts of 2-[(2-methoxy-5-fluorophenyl)azo]-1H-imidazole as a yellow-orange acicular crystalline substance. It melted at 204° C. (decomposed), when measured in accordance with the designation of the Japanese Pharmacopeia and had a maximum ultraviolet absorption spectrum (λmax) at 388 mμ.
Elementary Analysis:
______________________________________                                    
            C    H         N      F                                       
______________________________________                                    
Calculated (%)                                                            
              54.55  4.09      25.45                                      
                                    8.64                                  
Found (%)     54.60  4.12      25.58                                      
                                    8.69                                  
______________________________________                                    
EXAMPLE 3
To a solution of 4.04 parts of 4-bromo-2-aminoanisole and 5.2 parts of 35% hydrochloric acid in 60 parts of water was added 10 parts of water containing 1.38 parts of sodium nitrite at 0°-5° C., and then the diazotization reaction was carried out by stirring the mixture at 0°-5° C. for 1 hour. The resulting diazonium salt solution was then added at 0°-5° C. to a solution of 9.53 parts of imidazole, 1.2 parts of sodium hydroxide and 1.64 parts of sodium acetate in 80 parts of water, and the mixture was stirred at the same temperature for 1 hour to complete the coupling reaction, thereby forming a crude yellow-orange product. The crude product was filtered and dried at 60° C. to provide 5.1 parts of the product.
This crude product (4 parts) was then recrystallized from ethyl acetate to provide 3.2 parts of 2-[(2-methoxy-5-bromophenyl)azo]-1H-imidazole as a yellow-orange acicular crystalline substance. It melted at 224.5° C. (decomposed), when measured in accordance with the designation of the Japanese Pharmacopeia and had a maximum ultraviolet absorption spectrum (λmax) at 387 mμ.
Elementary Analysis:
______________________________________                                    
            C    H         N      Br                                      
______________________________________                                    
Calculated (%)                                                            
              42.70  3.20      19.93                                      
                                    28.44                                 
Found (%)     42.71  3.27      19.90                                      
                                    28.39                                 
______________________________________                                    
EXAMPLE 4
The procedure of one of the above examples was followed except for the type of the reactants and solvents, thereby providing 2-[(2-methoxyphenyl)azo]-1H-imidazole as a yellow columnar crystalline substance, m.p. 152°-153° C.
EXAMPLE 5
To a solution of 4.98 parts of 4-iodo-2-aminoanisole and 5.2 parts of 35% hydrochloric acid in 70 parts of water was added 10 parts of water containing 1.38 parts of sodium nitrite at 0°-5° C., and then the diazotization reaction was carried out by stirring the mixture at 0°-5° C. for 1 hour. The resulting diazonium salt solution was then added at 0°-5° C. to a solution of 10.89 parts of imidazole, 1.2 parts of sodium hydroxide and 1.64 parts of sodium acetate in 80 parts of water, and the mixture was stirred at the same temperature for 1 hour to complete the coupling reaction, thereby forming a crude yellow-orange product. The crude product was filtered, washed with water, and dried at 60° C. to provide 5.9 parts of the product.
This crude product (4.5 parts) was then column-chromatographed on silica gel to provide 3.5 parts of 2-[(2-methoxy-5-iodophenyl)azo]-1H-imidazole as a yellow-orange columnar crystalline substance. It melted at 217.5° C. (decomposed), when measured in accordance with the designation of the Japanese Pharmacopeia and had a maximum ultraviolet absorption spectrum (λmax) at 385 mμ.
Elementary Analysis:
______________________________________                                    
            C    H         N      I                                       
______________________________________                                    
Calculated (%)                                                            
              36.59  2.74      17.07                                      
                                    38.69                                 
Found (%)     36.61  2.70      17.09                                      
                                    38.61                                 
______________________________________                                    

Claims (7)

What is claimed is:
1. A compound represented by the formula: ##STR4## wherein X is halogen or an acid addition salt thereof.
2. The compound claimed in claim 1, wherein the compound is 2-[(2-methoxy-5-chlorophenyl)azo]-1H-imidazole.
3. The compound claimed in claim 1, wherein the compound is 2-[(2-methoxy-5-bromophenyl)azo]-1H-imidazole.
4. The compound claimed in claim 1, wherein the compound is 2-[(2-methoxy-5-iodophenyl)azo]-1H-imidazole.
5. The compound claimed in claim 1, wherein the compound is 2-[(2-methoxy-5-fluorophenyl)azo]-1H-imidazole.
6. A process for the high yield preparation of a compound of the formula ##STR5## wherein X is a hydrogen or halogen atom, or an acid addition salt thereof, comprising
reacting a compound of the formula ##STR6## wherein X is as previously defined with a nitrite and hydrochloric acid to form a diazonium compound, and
reacting the resulting diazonium compound of the above reaction with imidazole in a quantity of about 5 to 10 moles of imidazole per mole of diazonium compound to give the compound of formula (I) in a high yield.
7. A process as claimed in claim 6, further comprising converting the compound of formula I into an acid addition salt thereof.
US06/173,359 1979-07-30 1980-07-29 2-[(2-Methoxy-5-halo)azo]-1-H-imidazoles and method of production of 2-[(2-methoxy)azo]-1-H-imidazoles Expired - Lifetime US4507237A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP54097059A JPS6056123B2 (en) 1979-07-30 1979-07-30 Agent for treating edema, hypotension, heart failure, and mucosal hyperemia
JP54-97058 1979-07-30

Publications (1)

Publication Number Publication Date
US4507237A true US4507237A (en) 1985-03-26

Family

ID=14182075

Family Applications (2)

Application Number Title Priority Date Filing Date
US06/173,358 Expired - Lifetime US4315003A (en) 1979-07-30 1980-07-29 Compositions containing azo compounds and use thereof for therapeutic treatment
US06/173,359 Expired - Lifetime US4507237A (en) 1979-07-30 1980-07-29 2-[(2-Methoxy-5-halo)azo]-1-H-imidazoles and method of production of 2-[(2-methoxy)azo]-1-H-imidazoles

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US06/173,358 Expired - Lifetime US4315003A (en) 1979-07-30 1980-07-29 Compositions containing azo compounds and use thereof for therapeutic treatment

Country Status (5)

Country Link
US (2) US4315003A (en)
JP (1) JPS6056123B2 (en)
DE (1) DE3028927C2 (en)
FR (1) FR2462161A1 (en)
GB (1) GB2057874B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040242547A1 (en) * 2001-06-08 2004-12-02 Gristwood Robert William Arylazo-substituted imidazole for the treatment of stress urinary incontinence

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3133886A1 (en) * 1981-08-27 1983-03-17 Bayer Ag, 5090 Leverkusen 2-ARYLAZO-2-IMIDAZOLINE, ACYL DERIVATIVES THEREOF, METHOD FOR THE PRODUCTION THEREOF AND THE USE FOR COMBATING EKTO AND / OR ENDOPARASITES
JP4740846B2 (en) * 2003-07-22 2011-08-03 ファーマン,エスター,シー. Magnetic jewelry fastener with safety device and method for complete coupling of jewelry fastener
JP6607676B2 (en) * 2015-01-28 2019-11-20 花王株式会社 TRPV4 activator

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3102879A (en) * 1958-09-30 1963-09-03 Basf Ag Production of cationic dyestuffs
US3173907A (en) * 1959-11-27 1965-03-16 American Cyanamid Co Quaternized n-alkylated arylazoimidazoles
US3216995A (en) * 1959-06-22 1965-11-09 Basf Ag Method for the production of cationic dyestuffs
US3294777A (en) * 1963-11-23 1966-12-27 Basf Ag Production of heterocyclic azo dyes
US3357783A (en) * 1963-04-20 1967-12-12 Bayer Ag Process for dyeing and printing polypropylene fibers with monoazo dyestuffs
US3468871A (en) * 1964-03-26 1969-09-23 Bayer Ag Metal-containing monoazo dyestuffs
US3981885A (en) * 1971-06-15 1976-09-21 Bayer Aktiengesellschaft 2-Alkyl-phenylhydrazonomidazolenines

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4067973A (en) * 1976-12-27 1978-01-10 The Dow Chemical Company 2-((2-chlorophenyl)azo)imidazoles and their use as an anthelmintic
US4079130A (en) * 1976-12-27 1978-03-14 The Dow Chemical Company Antidepressant phenylazoimidazoles
DE2837953A1 (en) * 1978-08-31 1980-03-13 Bayer Ag CATIONIC DYES

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3102879A (en) * 1958-09-30 1963-09-03 Basf Ag Production of cationic dyestuffs
US3216995A (en) * 1959-06-22 1965-11-09 Basf Ag Method for the production of cationic dyestuffs
US3173907A (en) * 1959-11-27 1965-03-16 American Cyanamid Co Quaternized n-alkylated arylazoimidazoles
US3357783A (en) * 1963-04-20 1967-12-12 Bayer Ag Process for dyeing and printing polypropylene fibers with monoazo dyestuffs
US3294777A (en) * 1963-11-23 1966-12-27 Basf Ag Production of heterocyclic azo dyes
US3468871A (en) * 1964-03-26 1969-09-23 Bayer Ag Metal-containing monoazo dyestuffs
US3981885A (en) * 1971-06-15 1976-09-21 Bayer Aktiengesellschaft 2-Alkyl-phenylhydrazonomidazolenines

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Beilstein, "Handbuch der Organischen Chemie", vol. 24, 2nd Supplement, p. 37, (1954).
Beilstein, Handbuch der Organischen Chemie , vol. 24, 2nd Supplement, p. 37, (1954). *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040242547A1 (en) * 2001-06-08 2004-12-02 Gristwood Robert William Arylazo-substituted imidazole for the treatment of stress urinary incontinence

Also Published As

Publication number Publication date
US4315003A (en) 1982-02-09
FR2462161B1 (en) 1983-06-24
FR2462161A1 (en) 1981-02-13
JPS6056123B2 (en) 1985-12-09
GB2057874B (en) 1983-11-16
DE3028927A1 (en) 1981-02-26
GB2057874A (en) 1981-04-08
DE3028927C2 (en) 1984-10-31
JPS5620516A (en) 1981-02-26

Similar Documents

Publication Publication Date Title
EP0206435B1 (en) 2,4-dihalo-5-substituted phenylhydrazines and their production and use
US4584383A (en) Substituted 2-mercapto-imidazoles and their preparation
US3895028A (en) Alpha-(2-phenylbenzothiazol-5-yl)propionic acid
DD156260A1 (en) PREPARATION OF IMIDAZOLE DERIVATIVES
US4507237A (en) 2-[(2-Methoxy-5-halo)azo]-1-H-imidazoles and method of production of 2-[(2-methoxy)azo]-1-H-imidazoles
US4324899A (en) 2-Amino-5-cyanothiazoles and their preparation
DE2841644C2 (en)
US4158013A (en) N-Cyano-N'-alkynyl-N"-2-mercaptoethylguanidines
US4318915A (en) Substituted guandines and methods of preparation thereof
US5030738A (en) Synthesis of antiulcer compounds
GB2060671A (en) Azo Compounds
US3900486A (en) 3-methyl-2-phenyl-5-benzothiazoline acetic acid compounds and process for producing the same
US3378552A (en) Imidazole compounds and methods of making the same
US4188489A (en) Process for the production of 3-substituted amino-5-pyrazolones
DE2208368C3 (en) 1-phenyl-S-hydroxy-S-methyltriazenes and process for their preparation
EP0174519B1 (en) Process for the production of 1-amino-2-naphthol-4-sulphonic acid
US4236017A (en) Process for synthesizing 2-substituted semicarbazones and carbalkoxy hydrazones
DE2923817B1 (en) (3-alkylamino-2-hydroxypropoxy) -furan-2-carboxylic acid anilides and their physiologically tolerable acid addition salts and processes for their preparation and medicaments containing these compounds
US4266062A (en) (1-Methyl-2-pyridinylidene) derivatives of guanidine
IE42039L (en) Cycloalkanothiophenes
EP0054859B1 (en) Naphthalene derivatives, their preparation and their use
AT316744B (en) Process for the preparation of new acyloxyalkyl esters of 6- (α-aminophenylacetamido) -penicillanic acid, 7- (α-aminophenylacetamido) -desacetoxycephalosporanic acid and 7- (α-aminophenylacetamido) -cephalosporanic acid
SU626694A3 (en) Method of producing benzimidazole derivatives or their salts
US3453286A (en) Process for preparing cycloheptimidazolinium halides
AT349453B (en) PROCESS FOR THE PREPARATION OF NEW AMINOACETOPHENONE DERIVATIVES AND OF THEIR SALTS

Legal Events

Date Code Title Description
AS Assignment

Owner name: MOCHIDA SEIYAKU KABUSHIKI KAISHA 1-7, YOTSUYA, SHI

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:MOCHIDA EI;SUZUKI, YASUO;OHNISHI, HARUO;AND OTHERS;REEL/FRAME:004126/0187

Effective date: 19830414

Owner name: HODOGAYA CHEMICAL CO., LTD. 1-4-2, TORANOMON, MINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:MOCHIDA EI;SUZUKI, YASUO;OHNISHI, HARUO;AND OTHERS;REEL/FRAME:004126/0187

Effective date: 19830414

STCF Information on status: patent grant

Free format text: PATENTED CASE

CC Certificate of correction